|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2200059109 |
|
最近更新日期: Date of Last Refreshed on: |
2022-04-25 22:28:33 |
|
注册时间: Date of Registration: |
2022-04-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
术中使用血管活性药物对围术期神经认知障碍的影响:一项随机对照双盲实验 |
|
Public title: |
Effects of the use of vasoactive drugs in surgery on perioperative neurocognitive disorder: a randomized controlled double-blind trial |
|
注册题目简写: |
术中使用血管活性药物对围术期神经认知障碍的影响 |
|
English Acronym: |
Effects of the use of vasoactive drugs in surgery on perioperative neurocognitive disorder |
|
研究课题的正式科学名称: |
术中使用血管活性药物对围术期神经认知障碍的影响:一项随机对照双盲实验 |
|
Scientific title: |
Effects of the use of vasoactive drugs in surgery on perioperative neurocognitive disorder: a randomized controlled double-blind trial |
|
研究课题代号(代码): Study subject ID: |
无 |
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
无 |
|
申请注册联系人: |
毕燕琳 |
研究负责人: |
毕燕琳 |
|
Applicant: |
Yanlin Bi |
Study leader: |
Yanlin Bi |
|
申请注册联系人电话: Applicant telephone: |
18661675610 |
研究负责人电话:
Study leader's |
18661675610 |
|
申请注册联系人传真 : Applicant Fax: |
18661675610 |
研究负责人传真: Study leader's fax: |
18661675610 |
|
申请注册联系人电子邮件: Applicant E-mail: |
pndable2021@sina.com |
研究负责人电子邮件: Study leader's E-mail: |
pndable2021@sina.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
无 |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
无 |
|
申请注册联系人通讯地址: |
青岛市市立医院东院麻醉科市南区东海中路5号 |
研究负责人通讯地址: |
青岛市市立医院东院麻醉科市南区东海中路5号 |
|
Applicant address: |
Qingdao Municipal Hospital, 5, Dong-Hai Middle Road, Shi-Nan District, Qingdao |
Study leader's address: |
Qingdao Municipal Hospital, 5, Dong-Hai Middle Road, Shi-Nan District, Qingdao |
|
申请注册联系人邮政编码: Applicant postcode: |
266071 |
研究负责人邮政编码: Study leader's postcode: |
266071 |
|
申请人所在单位: |
青岛市市立医院 |
||
|
Applicant's institution: |
Qingdao Municipal Hospital |
||
|
研究负责人所在单位: |
青岛市市立医院 |
||
|
Affiliation of the Leader: |
Qingdao Municipal Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2021临审字Y第038号 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
青岛市市立医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethical Committee Qingdao Municipal Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2021-12-30 00:00:00 | ||
|
伦理委员会联系人: |
杨九龙 |
||
|
Contact Name of the ethic committee: |
Yanlin Bi |
||
|
伦理委员会联系地址: |
青岛市市立医院东院麻醉科市南区东海中路5号 |
||
|
Contact Address of the ethic committee: |
Qingdao Municipal Hospital, 5, Dong-Hai Middle Road, Shi-Nan District, Qingdao |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
18661675610 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
pndable2021@sina.com |
|
研究实施负责(组长)单位: |
青岛市市立医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Qingdao Municipal Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
青岛市市立医院东院麻醉科市南区东海中路5号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
Qingdao Municipal Hospital, 5, Dong-Hai Middle Road, Shi-Nan District, Qingdao |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
无 |
||||||||||||||||||||||
|
Source(s) of funding: |
No |
||||||||||||||||||||||
|
研究疾病: |
围术期神经认知障碍 |
||||||||||||||||||||||
|
Target disease: |
perioperative neurocognitive disorder |
||||||||||||||||||||||
|
研究疾病代码: |
无 |
||||||||||||||||||||||
|
Target disease code: |
无 |
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
探索性研究/预试验 | ||||||||||||||||||||||
|
Study phase: |
0 |
||||||||||||||||||||||
|
研究设计: |
随机平行对照 |
||||||||||||||||||||||
|
Study design: |
Parallel |
||||||||||||||||||||||
|
研究目的: |
术中通过选择合适的血管活性药物改善重要脏器的氧供和血供,同时可能降低围术期神经认知障碍的发生。 |
||||||||||||||||||||||
|
Objectives of Study: |
Intraoperative improvement of oxygen and blood supply to vital organs is improved by selecting appropriate vasoactive agents, which may reduce the incidence of perioperative neurocognitive disorders. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
在本次研究中,我们通过对术中管理患者血压的药物控制,来研究麻黄碱或去甲肾上腺素对患者围术期神经认知障碍的影响及可能存在的机制,可能有助于降低患者围术期神经认知障碍的发生率。 |
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
In this study, we studied the effect of ephedrine or norepinephrine on perioperative neurocognitive disorder and possible mechanisms through drug control of intraoperative management of patients' blood pressure, which may help reduce the incidence of perioperative neurocognitive disorder in patients. |
||||||||||||||||||||||
|
纳入标准: |
年龄40-90岁 ASA I-III级 无严重肝肾功能障碍 无精神药物成瘾史 进行腹部手术的患者 |
||||||||||||||||||||||
|
Inclusion criteria |
Age 40 to 90 years ASA Class I-III No severe liver and kidney dysfunction No history of psychotropic addiction Patients undergoing abdominal surgery |
||||||||||||||||||||||
|
排除标准: |
(1)中枢神经系统感染、头部外伤、或其他明显的神经系统疾病; (2) 严重的视力和听力障碍 (3) 严重精神或神经系统疾病史,如阿尔茨海默病、帕金森综合征、脑血管意外和脑血管疾病(4)术前简易精神状态检查量表(MMSE)≤23分(5)药物滥用或精神药物滥用,长期使用类固醇和激素类药物,(6)遗传病家族史(如早发性家族性AD、遗传性共济失调、遗传性痉挛性截瘫等)。 |
||||||||||||||||||||||
|
Exclusion criteria: |
(1) Central nervous system infection, head trauma, or other obvious neurological disorders; (2) Severe vision and hearing impairment (3) History of severe psychiatric or neurological disorders, such as Alzheimer's disease, Parkinson's syndrome, cerebrovascular accident and cerebrovascular disease (4) Preoperative Simple Mental Status Check Scale (MMSE) ≤ 23 points (5) Substance abuse or psychotropic substance abuse, long-term use of steroids and hormone drugs, (6) family history of genetic diseases (such as early-onset familial AD, hereditary ataxia). , hereditary spastic paraplegia, etc.). |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2022-04-15 00:00:00至 To 2023-05-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2022-04-15 00:00:00 至 To 2023-05-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
患者使用计算机生成的代码进行集中随机化,方块大小为4个,按试验地点和使用血管活性药类型进行分层。 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
Patients were centrally randomized using computergenerated codes with a block size of four, stratified by trial site and type of vasoactive drugs. |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
不公开/Private |
|
盲法: |
结果评估和统计分析均由研究人员独立进行。结果评估者和手术团队对研究参与者的分布视而不见。 |
|
Blinding: |
The outcome assessment and statistical analyses were conducted by researchers independently. Outcome assessors and the surgical team were blind to the distribution of participants in the study |
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
No |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
无 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
No |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
有/Yes |